New aspects concerning the pathophysiology of heart failure;Neue aspekte zur pathophysiologie der herzinsuffizienz

Wiener Medizinische Wochenschrift

Volumn 148, Issue 5, 1998, Pages 108-120

  Pieske, B ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Apoptosis; Excitation contraction coupling; Force frequency relation; Heart failure; Neuro endocrine activation

Indexed keywords

ADENYLATE CYCLASE; BETA ADRENERGIC RECEPTOR; CALCIUM ION; CYCLIC AMP; GUANINE NUCLEOTIDE BINDING PROTEIN; NITRIC OXIDE; SODIUM ION;

ADRENERGIC SYSTEM; APOPTOSIS; CARDIOVASCULAR DISEASE; EXCITATION CONTRACTION COUPLING; HEART CONTRACTION; HEART FAILURE; HEART FUNCTION; ION EXCHANGE; NEUROENDOCRINOLOGY; PATHOPHYSIOLOGY; REVIEW; SARCOPLASMIC RETICULUM;

ANIMALS; CALCIUM; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HUMANS; MYOCARDIAL CONTRACTION; NEUROSECRETORY SYSTEMS; SODIUM-CALCIUM EXCHANGER;

EID: 0031954485     PISSN: 00435341     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (168)

1. Allen DG, Kurihara S: The effects of muscle length on intracellular calcium transients in mammalian cardiac muscle. J Physiol 1982; 327:79-94.
2. Allen DG. Kentish JC: Calcium concentration in the myoplasm of skinned ferret ventricular muscle following changes in muscle length. J Physiol 1988:407:489-503.
3. Alpert NR, Gordon M: Myofibrillar adenosine triphosphatase activity in congestive heart failure. Am J Physiol 1962:20:940-946.
4. Anderson PA, Malouf NN, Oakeley AE. Pagani ED, Allen PD: Troponin T isoform expression in humans. A comparison among normal and failing adult heart, fetal heart, and adult and fetal skeletal muscle. Circ Res 1991:69:1226-1233.
5. Anderson PAW, Greig A, Mark TM, Malouf NN, Oakeley AE, Ungerleider RM, Allen PD, Kay BK: Molecular basis of human cardiac troponin T isoforms expressed in the developing, adult, and failing heart. Circ Res 1995:76:681-686.
6. Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW: Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993:91:2314-2319.
7. Bayliss J, Norell M, Canepa-Anson R, Sutton G, Poole-Wilson P: Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987:57:17-22.
8. Beuckelmann DJ, Nabauer M, Erdmann E: Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992:85:1046-1055.
9. 2+)i-transients in single ventricular myocytes isolated from terminally failing human myocardium. Bas Res Cardiol 1992:87 (suppl 1): 235-243.
10. Bishop J, Greenbaum J, Gibson D, Yacoub MH, Laurent GJ: Enhanced deposition of predominantly type I collagen in myocardial disease. J Moll Cell Cardiol 1990:22:1157-1165.
11. Böhm M, Beuckelmann D, Brown L, Feiler G, Lorenz B, Näbauer M, Kemkes B, Erdmann E: Reduction of beta-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 1988:9:844-852.
12. Böhm M, Diet F, Pieske B, Erdmann E: Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Meth 1989:699:33-44.
13. Böhm M, Eschenhagen T, Giershick P, et al: Radioimmunochemical quantification of Gia in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominantly left ventricular failure. J Moll Cell Cardiol 1994:26:133-149.
14. Böhm M, Reiger B, Schwinger RHG, Erdmann E: cAMP concentrations. cAMP dependent protein kinase activity and phospholamban in non-failing and failing myocardium. Cardiovasc Res 1994:28: 1713-1719.
15. Bowditch HP: Über die Eigentümlichkeiten der Reizbarkeit, welt-he die Muskelfasern des Herzens zeigen. Ber Sachs Ges (Akad) Wiss 1871:23:652-689.
16. Brenner B, Eisenberg E: Rate of force generation in muscle: correlation with actomyosin ATPase activity in solution. Proc Nall Acad Sci 1986:83:3542-3546.
17. Brillantes A-M, Allen P, Takahashi T. Izumo S, Marks AR: Differences in cardiac calcium release channel (ryanodine receptor) expression in myocardium from patients with end-stage heart failure caused by ischemie versus dilated cardiomyopathy. Circ Res 1992:71 : 18-26.
18. Bristow MR, Ginsburg R, Minobe W, Cubiciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DE, Stinson EB: Decreased catecholamine sensitivity and β-adrenergic receptor density in failing human hearts. N Engl J Med 1982:307:205-211.
19. 2-Adrenoceplors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991:43:203-242.
20. Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM: Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995:92: 8031-8035.
21. Cheng H, Lederer WJ, Cannell MV: Calcium sparks: Elementary events underlying excitation-contraction coupling in heart muscle. Science 1993:87:1806-1815.
22. Coats AJS, Clark AL, Piepoli M, Volterrrani, Poole-Wilson: Symptoms and quality of life in heart failure: the muscle hypothesis. Br Heart J 1994:72 (suppl): S36-S39.
23. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
24. Cohn JN: The sympathetic nervous system in heart failure. J Cardiovasc Pharmacol 1989:14 (suppl 5): 57-61.
25. Conway MA, Allis J, Ouwerkerk R, Niioka T, Rajagopalan B, Radda GK: Detection of low phosphocreatine to ATP ratio in failing hypertrophied human myocardium by 31P magnetic resonance spectroscopy. Lancet 1991:338:973-976.
26. 2+ release activity of the sarcoplasmic reticulum in dilated cardiomyopathy. Circulation 1992:85:518-525.
27. Danielsen W, von der Leyen H, Meyer W, el al: Basal and isoprenaline-stimulated cyclic AMP in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 1989:14:171-173.
28. DeBelder AJ, Radomski MW, Why HJF, Richardson PJ, Bucknall CA, Salas E, Marin JF, Moncada S: Nitric oxide synthase activities in human myocardium. Lancet 1993:341:84-85.
29. Deng MC, Roeder N, Plenz G, Erren M, Brisse B, Soeparwata R, Scheld HH: Proinflammatorische Zytokine und kardiale Pumpfunktion. Z Kardiol 1997:86:788-802.
30. Dhalla NS, Wang X, Beamish RE: Intracellular calcium handling in normal and failing hearts. Exp Clin Cardiol 1996:1:7-20.
31. Drexler H: Skeletal muscle failure in heart failure. Circulation 1992:85:1261-1263.
32. Drexler H, Riede U, Munzel T, Knight H, Funke E, Just H: Alterations of skeletal muscle in chronic heart failure. Circulation 1992:85:1751-1759.
33. Dzau V, Colucci W, Hollenberg N, Williams G: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981:63:645 656.
34. Eisenhofer G, Friberg P, Rundquist B, Quyyumi AA, Lambert G, Kaye DM, Kopin IJ, Goldstein DS, Esler MD: Cardiac sympathetic function nerve in congestive heart failure. Circulation 1996:3:1667-1676.
35. Elsner D, Riegger GA: Characteristics and clinical relevance of animal models of heart failure. Curr Opin Cardiol 1995:10:253-259.
36. Erdmann E: Therapie der chronischen Herzinsuffizienz mit positiv inotropen Pharmaka. Internist 1986:27:298-305.
37. Fabiato A: Calcium-induced release of calcium from cardiac sarcoplasmic reticulum. Am J Physiol 1983;245:C1-C14.
38. Feldmann MD, Aldermann JD, Aroesti JM, Royal HD, Ferguson JJ, Owen RM, Grossmann W, McKay RG: Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 1988:82:1661-1669.
39. Feldmann MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossmann W, Morgan JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 1987:75:331-339.
40. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassant G, Visioli O: Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995:92:1479-1486.
41. Fink LI, Wilson JR, Ferraro N: Exercise ventilation and pulmonary capillary wedge pressure in chronic stable congestive heart failure. Am J Cardiol 1986:57:249-253.
42. Finkel MS, Oddis CV, Jakob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992:257:387-389.
43. 2+ exchanger in failing human myocardium. Circulation 1996:94:992-1002.
44. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990:82:1724 1729.
45. Francis GS, Cohn JN, Johnson G, Rector TS, Goldmann S, Simon A: Plasma norepinephrine. plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT VA Cooperative Studies Group. Circulation 1993:87 (suppl 6): 40-48.
46. Gibbs JSR, Keegan J, Wright C, Fox KM, Poole-Wilson PA: Pumonary artery changes during exercise and daily activities in chronic heart failure. J Am Coll Cardiol 1990:15:52-61.
47. Go LO, Moschella MC, Watras J. Handa KK, Fyfe BS, Marks AR: Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. J Clin Invest 1995:95:888-894.
48. Gorza L, Mercadier JJ, Schwartz K, Thornell LE, Sartore S, Schiaffino S: Myosin types in the human heart. An immunofluorescence study of normal and hypertrophied atrial and ventricular myocardium. Circ Res 1984:54:694-702.
49. Grassi G, Seravalle G, Cattaneo BM, Lanfranchi A, Vailati S, Giannattasio C, Del Bo A, Sala C, Bolla GB, Pozzi M: Sympathetic activation and loss of reflex sympathetic control in mild congestive heart failure. Circulation 1995:92:3206-3211.
50. Gulati J: Length-sensing function of troponin C and Starling's law. Circulation 1992:85:1954-1955.
51. Gulick T, Pieper SJ, Murphy MA, Lange LG, Schreiner GF: A new method for assessment of cultured cardiac myocyte contractility detects immune-factor mediated inhibition of β-adrenergic responses. Circulation 1991:84:313-321.
52. Gunteroth WG, Jaeki JP, Kawabori I, Stevenson JG, Moreno AH: Left ventricular performance in endotoxin shock in dogs. Am J Physiol 1982:242:H172 H176.
53. 2+. Circulation 1990:82:1266-1278.
54. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G: Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991:122:795-801.
55. Hare JM, Loh E, Creager MA, Colueci WS: Nitric oxide inhibits the positive inotropic response to β-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995:92:2198-2203.
56. Hasenfuss G, Mulieri LA, Leavitt BJ, Alien PD, Haeberle JR, Alpert NR: Alteration of contractile function and excitation-contraction coupling in dilated cardiomyopathy. Circ Res 1992:70:1225-1232.
57. Hasenfuss G, Preuss M, Lehnart S, Preslle J, Meyer M, Just H: Relationship between diastolie function and protein levels of sodiumcalcium-exchanger in end-stage failing human heart. Circulation 1996:94 (suppl 1): 433.
58. Hasenfuss G, Holubarsch C, Hermann HP, Astheimer K, Pieske B, Just H: Influence of the force-frequency relationship on haemodynamics and left ventricular function in patients with non-failing hearts and in patients with dilated cardiomyopathy. Eur Heart J 1994:15:164-170.
59. 2+-AT-Pase in failing and nonfailing human myocardium. Circ Res 1994: 75:434-442.
60. Hegewish S, Weh HJ, Hossfeld DK: TNF-induced cardiomyopathy. Lancet 1990:338:294-295.
61. Ho KKL, Anderson KM, Kannel WB, Grossmann W, Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993:88:107-115.
62. Holubarsch C, Hasenfuss G, Schmidt-Schweda S, Knorr A, Pieske B, Ruf T, Fasol R, Just H: Angiotensin 1 and 2 exert inotropic effects in atrial but not in ventricular human myocardium. Circulation 1993:88:1228-1237.
63. Holubarsch C, Ruf T, Goldstein D, Ashton RC, Nickl W, Pieske B, Pioch K, Lüdemann J, Wiesner S, Hasenfuss G, Posival H, Just H, Burkhoff D: Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere level. Circulation 1996:94:683-689.
64. Hornig B, Maier V, Drexler H: Physical training improves endothelial function in patients with chronic heart failure. Circulation 1996:93:212-214.
65. Jondeau G, Katz SD, Zohman L, Goldberger M, McCarthy M, Boudarias JP, LeJemtel TH: Active skeletal muscle mass and cardiopulmonary reserve. Failure to attain peak aerobic capacity during maximal bicycle exercise in patients with severe congestive heart failure. Circulation 1992:86:1351-1356.
66. Kajstura J, Mansukhani M, Cheng W, Reiss K. Krajewski S. Reed JC, Quaini F, Sonnenblick EH, Anversa P: Programmed cell death and expression of the protooncogene bcl-2 in myocytes during postnatal maturation of the heart. Exp Cell Res 1995:219:110-121.
67. Kajstura J, Zhang X, Reiss K, Szoke E, Li P, Lagrasta C, Cheng W. Darzynkiewicz Z, Olivetti G, Anversa P: Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing induced cardiomyopathy in rats. Circ Res 1994:74:383-400.
68. Katz SD, Krum H, Khan T, Knecht M: Exercise-induced vasodilation in forearm circulation of normal subjects and patients with congestive heart failure: role of endothelium-derived nitric oxide. J Am Coll Cardiol 1996:28:585-590.
69. Katz SD, Schwarz M, Yuen JL, Lejemtel TH: Impaired acetylcholine-mediated vasodilation in patients with congestive heart failure: role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993:88:55 61.
70. Katz SD: Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 1997:12:259-264.
71. Komamura K, Shannon RP, Ihara T, Shen YT, Mirsky I, Bishop SP, Vatner SF: Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993:265:H1119-H1131.
72. Kubo SH, Rector TS, Bank AJ, Williams RE, Heifetz SM: Endothelium-dependent vasodilation is attenuated in patients with heart failure. Circulation 1991:84:1589-1596.
73. Lakatta EG: Determinants of cardiovascular performance: Modifications due to aging. J Chronic Dis 1983:36:15-30.
74. LeJemtel TH, Sonnenblick EH: Heart failure: adaptive and maladaptive processes. Circulation 1993:87 (suppl VII): VII1-VII4.
75. Lentz RW, Harrison CE jr, Dewey JD, Bamhorst DA, Danielson GK, Pluth JR: Functional evaluation of cardiac sarcoplasmic reticulum and mitochondria in human pathologic states. J Moll Cell Cardiol 1978:10:3-30.
76. Levine B, Kalmann J, Mayer L, Fillit HM, Packer M: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990:323:236-241.
77. Limas CJ, Olivari M-T, Goldenberg IF, Levine TB, Benditt DG, Simon A: Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987:21:601-605.
78. Linck B, Boknik P, Eschenhagen T, Müller FU, Neumann J, Nose M, Jones LR, Schmilz W, Scholz H: Messenger RNA expression and immunological quantification of phospholamban and SR-Ca2+-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996:31:625-632.
79. Linzbach AJ: Heart failure from the point of view of quantitative anatomy. Am J Cardiol 1960:5:370-382.
80. Little WC, Ohno M, Kitzman DW, Thomas JD, Cheng CP: Determination of left ventricular chamber stiffness from the time for deceleration of early left ventricular filling. Circulation 1995:92:1933-1939.
81. Liu Y, Cigola E, Cheng W, Kajstura J, Olivetti G, Hintze TH, Anversa P: Myocyte nuclear mitotic division and programmed myocyte cell death characterize the cardiac myopathy induced by rapid ventricular pacing in dogs. Lab Invest 1995:73:771-787.
82. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J: Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 1994:89:2760-2767.
83. Mancini DM, Ferraro N, Tuchler M, Chance B, Wilson JR: Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonance. Am J Cardiol 1988:62:1234-1240.
84. 31P NMR skeletal muscle abnormalities in patients with chronic heart failure. Circulation 1989:80:1338-1346.
85. Mancini DM, Walter G, Reichek N, Lenkinski R, McCully KK, Mullen JL, Wilson JR: Contribution of skeletal muscle atrophy to exercise intolerance and altered muscle metabolism in heart failure. Circulation 1992:85:1364-1373.
86. Margossian SS, White HD, Caulfield JB, Norton P, Taylor S, Slayter HS: Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of causal agent for impaired myocardial function. Circulation 1992:85:1720-1733.
87. Maskin CS, Forman R, Sonnenblick EH, Frishman WH, LeJemtel TH: Failure of dobutamine to increase exercise capacity despite haemodynamic improvement in severe chronic heart failure. Am J Cardiol 1983:51:177-182.
88. Massie B, Conway M, Yonge R, Frostick S, Sleight P, Ledingham J, Radda G, Rajagopalan B: 31-P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failure. Am J Cardiol 1987:60:309-315.
89. Massie B, Conway M, Yonge R, Frostick S, Ledingham J, Sleight P, Radda G, Rajagopalan B: Skeletal muscle metabolism in patients with congestive heart failure: relation to clinical severity and blood flow. Circulation 1987:76:1009-1019.
90. Matsumori A, Yamada T, Suzuki H, Matoba Y, Sasayama S: Increased circulating cytokines in patients with myocarditis and cardiomyopathy. Br Heart J 1994:72:561-566.
91. Mercadier JJ, Bouveret P, Gorza L, Schiafflno S, Clark WA, Zak R, Swynghedauw B, Schwartz K: Myosin isoenzymes in normal and hypertrophied human ventricular myocardium. Circ Res 1983:53:52-62.
92. 2+-ATPaSe gene expression in the human ventricle during end-stage heart failure. J Clin Invest 1990:85:305-309.
93. Mewes T, Ravens U: L-type calcium currents of human myocytes from ventricle of non-failing and failing hearts and from atrium. J Moll Cell Cardiol 1994:26:1307-1320.
94. Meyer M, Schillinger W, Pieske B, Holubarsch C, Heilmann C, Posival H, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G: Alterations of sarcoplasmic reticulum proteins in failing human dilated cardiomyopathy. Circulation 1995:92:778-784.
95. Moncada A, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993:329:2002-2012.
96. 2+-regulation of mechanical properties of striated muscle: Mechanistic studies using extraction and replacement of regulatory proteins. Circ Res 1992:70:865-884.
97. Mulieri LA, Hasenfuss G, Leavitt B, Allen PD, Alpert NR: Altered myocardial force-frequency relation in human heart failure. Circulation 1992:87:199-212.
98. Mulieri LA, Leavitt BJ, Martin BJ, Haeberle JR, Alpert NR: Myocardial force-frequency defect in mitral regurgitation heart failure is reversed by forskolin. Circulation 1993:88:2700-2704.
99. Narula J, Haider N, Virmani R, DiSalvo TG, Kolodgie FD, Hajjar RJ. Schmidt U, Semigran MJ, Dec GW, Khaw BA: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996:335:1182-1189.
100. 31P-magnetic resonance spectroscopy of volunteers and patients with coronary artery disease and dilated cardiomyopathy: altered cardiac high-energy phosphate metabolism in heart failure. Circulation 1992; 86:1810-1818.
101. 31P-magnetic resonance spectroscopy to the understanding of dilated heart muscle disease. Eur Heart J 1995;16(suppl 0): 115-118.
102. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS: Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Circulation 1997:96:2178-2182.
103. 2+ accumulation in nonfailing and failing human myocardium. Circulation 1995:92: 2504-2510.
104. Nishigaki K, Minatoguchi S, Asano K, Noda T, Sano H, Kumada H, Tanaka T, Watanabe S, Seishima M, Fujiwara H: Plasma levels of soluble Fas and Fas ligand. apoptosis signaling receptor molecular, in patients with congestive heart failure. Circulation 1996:94 (suppl I): 1-32.
105. Oddis CV, Simmons RL, Hattler BG, Finkel MS: Chronotropic effects of cytokines and the nitric oxide synthase inhibitor. L-NMMA, on cardiac myocytes. Biochem Biophys Res Comm 1994:205:992-997.
106. Osterziel KJ, Dietz R: Therapie der Herzinsuffizienz mit β-Blok-kern? Z Kardiol 1997:86:1-8.
107. Pacher R, Stanek B, Hulsmann M, Koller-Strametz J, Berger R, Schuller M, Hartter E, Ogris E, Frey B, Heinz G, Maurer G: Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996:27:633-641.
108. Packer M: Neurohormonal interactions and adaptations in congestive heart failure. Circulation 1988:77:721-730.
109. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis GI, Sollano JA, Shannon J, Tandon PK, DeMets DL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991:325:1468-1475.
110. Pagani ED, Alousi AA, Grant M, Older TM, Dziuban SW, Allen PD: Changes in myofibrillar content and Mg-ATPase activity in ventricular tissue from patients with dilated heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 1988:63:380-385.
111. Pagani FD, Baker LS, Hsi C, Knox M, Fink MP, Visner MS: Left ventricular systolic and diastolic dysfunction after infusion of tumornecrosis factor "in conscious dogs. J Clin Invest 1992:90:389-398.
112. 2+ transient in isolated bundles of skeletal muscle fibers from rats with chronic heart failure. Circ Res 1993:73:405-412.
113. 2+-independent regulation of contractility in isolated human myocardium. Basic Res Cardiol 1992 (suppl 1): 75-86.
114. Pieske B, Kretschmann B, Meyer M, Holubarsch C, Weirich J, Posival H, Minami K, Just H, Hasenfuss G: Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 1995:92:1169-1178.
115. 2+ handling. J Clin Invest 1996:98:764-776.
116. Pieske B, Beyermann B, Duis J, Clozel M, Breu V: Endothelin-1 increases contractility in human dilated cardiomyopathy via an upregulated ETA receptor subtype. Circulation 1996:94:1-406.
117. 2+-content in myocardium from patients with heart failure. Circulation 1997:96 (suppl): 1-199.
118. Pinsky DJ, Cai B, Yang X, Rodriguez C, Sciacca RR, Cannon PJ: The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor?. J Clin Invest 1995;95:677-685.
119. Plot C, Lemalre S, Albat B, Seguin J, Nargeot J, Richard S: High frequency-induced upregulation of human cardiac calcium currents. Circulation 1996;93:120-128.
120. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB. Chang PI: Randomised trial of losartari versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349:747-752.
121. Pousset F, lsnard R, Lechat P, Kalotka H, Carayon A, Maistret G, Escolanos S, Thomas D, Komajda M: Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 1997;18:254-258.
122. Rasmussen RP, Minobe W, Bristow MR: Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol 1990;39:691-696.
123. Refenberick DH, Gamble JG, Max SR: Response of milochondrial enzymes to decreased muscular activity. AmJ Physiol 1973;225: 1259-1259.
124. 2+ exchange activity in patients with end-stage heart failure. Cardiovasc Res 1996:31:48-54.
125. Rundquist B, Elam M, Bergmann-Sverrisdottir Y, Eisenhofer G, Friberg P: Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure. Circulation 1997;95: 169-175.
126. Savin WM, Haskell WL, Schroeder JS, Stinson EB: Cardiopulmonary responses of cardiac transplant patients to graded, symptom limited exercise. Circulation 1980;62:55-60.
127. Schillinger W, Meyer M, Kuwajima G, Mikoshiba K, Just H, Hasenfuss G: Unaltered ryanodine receptor protein levels in ischemic cardiomyopathy. Mol Cell Biochem 1996;160/161:297-302.
128. Sehultheiss HP, Schulze K, Schauer R, Witzenbichler B, Strauer BE: Antibody-mediated imbalance of mvocardial energy metabolism. A causal factor of cardiac failure? Circ Res 1995;76:64-72.
129. Schwinger RHG, Böhm M, Erdmann E: lnotropic and lusitropic dysfunction in myocardium from patients with dilated cardiomyopathy. Am Heart J 1992;123:116-126.
130. Schwinger RHG, Böhm M, Koch A, Schmidt U, Morano I, Eissner HJ, Überfuhr R, Reichart B, Erdmann E: The failing human heart is unable louse the Frank-Starling mechanism. Circ Res 1994;74:959-969.
131. 2+-AT-Pase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. Circulation 1995;92:3220-3228.
132. Shan K, Kurrelmeyer K, Seta Y, Wang F, Dibbs Z, Deswal A, Lee-Jackson D, Mann DL: The role of cytokines in disease progression in heart failure. Curr Opin Cardiol 1997;12:218-223.
133. Sheng ZL. Pennica D, Wood WI, Chien KR: Cardiotrophin-1 displays early expression in the murine heart tube and promotes cardiac myocyte survival. Development 1996;122:419-428.
134. Simionif A, Long CS, Yue P, McElhinny, Dudley G, Massie BM: Heart failure in rats causes changes in skeletal muscle phenotype and gene expression unrelated to locomoler activity. Circulation 1995;92 (Suppl 1):1-259.
135. Soils RT, Downing SE: Effects of E. coli endotoxemia on ventricular performance. Am J Physiol 1966;211:307-311.
136. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M: Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 1996;28:1631-1639.
137. 2+-exchanger in end-stage human heart failure. Circ Res 1994; 75:443-453.
138. Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA Parillo JE: The cardivascular response of normal humans to the administration of endotoxin. N Engl J Med 1989;321:280-287.
139. Sullivan MJ, Green HJ, Cobb FR: Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990;81:518-527.
140. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJS: Insulin resistance in chronic heart failure. Eur Heart J 1994;15:1528-1532.
141. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 1992;90:927-935.
142. Takeda K, Yu ZX, Nishikawa T, Tanaka M, Hosoda S, Ferrans VJ, Kasajima T: Apoptosis and DNA fragmentation in the bulbus cordis of the developing rat heart. J Mol Cell Cardiol 1996;28:209-215.
143. The Consensus Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987; 316:1429-1435.
144. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
145. Torre-Amione G, Kapiada S, Lee J, Bies RD, Lebovitz R, Mann DL: Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995;1487-1493.
146. Torre-Amione G, Kapadia S, Lee J, Bies RD, Young JB, Mann DL: Tumor-necrosis factor-α and tumor-necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711.
147. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the study of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
148. Treasure CB, Vita JS, Cox DA, Fish RD, Gordon JB, Mudge GH, Colucci WS, Sutton MGSJ, Selwyn AP, Alexander RW: Endotheliumdependent dilation of the coronary microvasculature is impaired in dilated cardiomyopathy. Circulation 1990;81:772-779.
149. Ungerer M, Böhm M, Elce SJ, Erdmann E, Lohse MJ: Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 1993;454-463.
150. Unverferth DV, Lee SW, Wallick ET: Human myocardial adenosine triphosphatase activities in health and heart failure. Am Heart J 1988;115:139-146.
151. Vahl CF, Timek T, Bonz A, Kochsiek N, Fuchs H, Schäffer L, Rosenberg M, Dillmann R, Hagl S: Myocardial length-force relationship in end stage dilated cardiomyopathy and normal human myocardium: analysis of intact and skinned left ventricular trabeculae obtained during II heart transplantations. Basic Res Cardiol 1997; 92:261-270.
152. Vescovo G, Facehini L, Tenderini P, et al: A new micromcthod for assessing myosin heavy chain composition in skeletal muscle needle biopsies. Differences between chronic heart failure and disuse muscle atrophy. Eur Heart J 1995;16 (suppl): 357.
153. Villari B, Campbell SE, Hess OM, Mall G, Vassalli G, Weber KT, Krayenbuehl HP: Influence of collagen network on left ventricular systolic and diastolic function in aortic valve disease. J Am Coll Cardiol 1993;22:1477-1448.
154. Volterrani M, Clark AL, Ludman PF, Swan JW, Adamopoulos S, Piepoli M, Coats AJ: Predictors of exercise capacity in chronic heart failure. Eur Heart J 1994;15:801-809.
155. Von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, et al: Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to non-failing human cardiac muscle preparations. NS Arch Pharmacol 1991;344:90-100.
156. Waagstein F, Sweedberg K, Hjalmarson A: Improvement after metoprolol in idiopathic dilated cardiomyopathy is predicted by baseline systolic blood pressure and change in heart rate. J Am Coll Cardiol 1996;27:170A.
157. Wankerl M, Böhm M, Morano I, Rüegg JC, Eichhorn M, Erdmann E: Calcium sensitivity and myosin light chain pattern of atrial and ventricular skinned cardiac fibres from patients with various kinds of cardiac disease. J Mol Cell Cardiol 1990;22:1425-1438.
158. Weber KT, Wilson JR, Janicki J, Likoff MJ: Exercise testing in the evaluation of the patient with chronic cardiac failure. Am Rev Respir Dis 1984;129 (suppl): S60-S62.
159. Weyrich AS, Ma XL, Buerke M, Murohara T, Armstedt VE, Lefer AM, Nicolas JM, Thomas AP, Lefer DJ, Vinten-Johansen J: Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated
160. Wiechmann RJ, Wollmering M, Bristow MR: IL-I inhibits β-adrenergic responsiveness in intact human ventricular myocardium. J Am Coll Cardiol 1991;12:57A.
161. Wilson JR, Mancini DM, Dunkman WB: Exertional fatigue due to skeletal muscle dysfunction in patients with heart failure. Circulation 1993;87:470-475.
162. Wilson JR: Exercise intolerance in heart failure. Importance of skeletal muscle. Circulation 1995;91:559-561.
163. Wilson JR, Douglas P, Hiekey WF, Lanoce V, Ferraro N. Muhammad A, Reichek N: Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. Circulation 1987;75:857-867.
164. Wolff MR, Buck SH, Stoker SW, Greaser ML, Mentzer RM: Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrencrgically mediated protein phophorylation. J Clin Invest 1996;98:167-176.
165. Wroblewski H, Sindrup JH, Norgaard T, Haunso S, Kasirup J: Effects of orthotopic cardiac transplantation on structural microangiopathy and abnormal hemodynamics in idiopathic dilated cardiomyopathy. Am J Cardiol 1996;77:281-285.
166. Yates JC, Beamish RE, Dhalla NS: Ventricular dysfunction and necrosis produced by adrenochrome metabolite of epinephrine: relation to pathogenesis of catecholamine cardiomyopathy. Am Heart J 1981;102:210-221.
167. Yokoyama T, Vaca L, Rossen RD, Durante W, Hzarika P, Mann DL: Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest 1993;92:2303-2312.
168. Yoshizumi M, Perrela MA, Burnett JC Jr, Lee ME: Tumor-necrosis factor downrcgulates an endothelial nitric oxide mRNA by shortening its half-life. Circ Res 1993;73:205-209.